Evidence map›Paper›PMID 41739902›Full record

ArticleScience translational medicine2026

Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia.

Alexander Arnuk, Cuijuan Han, Abimbola E Lawal, Bofei Wang, Sadik Karma, Zhiping Zhang, Mhd Yousuf Yassouf, Sakthi Harini Rajendran, Harshpreet Chandok, Madeline L Eller and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Alexander ArnukJackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.ORCID 0000-0002-7134-6282
Cuijuan HanJackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.ORCID 0000-0002-7165-7785
Abimbola E LawalJackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.ORCID 0009-0001-1696-968X
Bofei WangDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77030 TX, USA.ORCID 0000-0003-3651-6802
Sadik KarmaJackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.ORCID 0000-0001-6401-9948
Zhiping ZhangDepartment of Genetics and Genome Sciences, UConn Health, Farmington, CT 06032, USA.ORCID 0000-0002-0116-9719
Mhd Yousuf YassoufDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77030 TX, USA.ORCID 0000-0001-7196-9503
Sakthi Harini RajendranJackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.ORCID 0000-0002-3319-7140
Harshpreet ChandokJackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Madeline L EllerGraduate Program in Genetics and Development, UConn Health, Farmington, CT 06032, USA.ORCID 0009-0004-6484-0727
Sogand SajediDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77030 TX, USA.ORCID 0009-0008-4157-5579
Meryl McKennaJackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.ORCID 0009-0006-0230-9046
Eve HermanJackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.ORCID 0009-0002-0624-7998
Louisa HagenJackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.ORCID 0009-0005-5034-8149
Bettina NadorpDepartment of Pathology and Perlmutter Cancer Center, New York University (NYU) School of Medicine, New York, NY 10016, USA.ORCID 0000-0003-1974-8425
Zengshuo MoGraduate Program in Genetics and Development, UConn Health, Farmington, CT 06032, USA.
Hector OrellanaJackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.ORCID 0000-0002-5994-3797
Aristotelis TsirigosDepartment of Pathology and Perlmutter Cancer Center, New York University (NYU) School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-7512-8477
Pedro MiuraDepartment of Genetics and Genome Sciences, UConn Health, Farmington, CT 06032, USA.ORCID 0000-0002-8434-5027
Hussein A AbbasDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77030 TX, USA.ORCID 0000-0003-2946-3562
Iannis AifantisDepartment of Pathology and Perlmutter Cancer Center, New York University (NYU) School of Medicine, New York, NY 10016, USA.ORCID 0000-0001-6857-1035
Eric WangJackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.ORCID 0000-0001-7865-6702

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI Paul Robson · 1985 to 2026
$61.9M
The impact of changes in chromatin architecture on cancer phenotypes and tumor progressionP01CA229086 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 2019 to 2026
$17.0M
Xenotransplant and Genome Editing CoreU54DK126108 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Daniel Starczynowski, YI ZHENG · 2021 to 2026
$5.0M
Dissecting innate immune signaling in pre-leukemia evolutionR01CA271455 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Iannis Aifantis, Daniel Starczynowski · 2022 to 2026
$3.2M
Scope and mechanism of coordinated alternative splicing and alternative polyadenylationR35GM138319 · NIGMS · UNIVERSITY OF NEVADA RENO · PI Pedro Miura · 2020 to 2026
$3.0M
Targeting an RNA Binding Protein Network in Acute Myeloid LeukemiaR01CA242020 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, AIFANTIS, IANNIS · 2020 to 2024
$2.7M
Regulation of emergency hematopoiesis by the ubiquitin-proteasome systemR01HL159175 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI AIFANTIS, IANNIS, BUSINO, LUCA · 2021 to 2024
$2.5M
Mechanisms of enhancer regulation in leukemiaR01CA228135 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2019 to 2023
$2.5M
JAX Diversity Action Plan (DAP) Post-Baccalaureate Program in Genomics (gDAP)R25HG012733 · NHGRI · JACKSON LABORATORY · PI BECK, CHRISTINE R, BULT, CAROL J · 2023 to 2025
$756k
NCI NIH HHS P01 CA229086NCI NIH HHS P30 CA034196NCI NIH HHS R01 CA228135NCI NIH HHS R01 CA242020NCI NIH HHS R01 CA271455NHGRI NIH HHS R25 HG012733NHLBI NIH HHS R01 HL159175NIDDK NIH HHS U54 DK126108NIGMS NIH HHS R35 GM138319
6 · The paper itself

Abstract

Inactivation of tumor suppressor genes (TSGs) imparts a cellular fitness in cancers, including in acute myeloid leukemia (AML). The detection of silenced TSGs without direct mutations presents challenges in designing targeted cancer treatments, yet it also opens a therapeutic opportunity to restore their function. In this study, we identified the transcriptional repressor

Identifiers

PMID41739902
PMCPMC13038048

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.